Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy

The evolving natural history of neurophysiologic function in patients with well-controlled diabetes

(2013) Christopher H. Gibbons et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Effects of Long-Term Treatment with Ranirestat, a Potent Aldose Reductase Inhibitor, on Diabetic Cataract and Neuropathy in Spontaneously Diabetic Torii Rats

(2013) Ayumi Ota et al.   Journal of Diabetes Research

Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy

(2012) Roman Stavniichuk et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy and Safety of Antioxidant Treatment With  -Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 trial

(2011) D. Ziegler et al.   DIABETES CARE

Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics

(2009) K. Van Acker et al.   DIABETES & METABOLISM

Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy

(2009) V. Bril et al.   DIABETES CARE

Diabetic Neuropathy in Older Adults

(2008) Aaron I. Vinik et al.   CLINICS IN GERIATRIC MEDICINE

Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy

(2008) Peter Oates   CURRENT DRUG TARGETS

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study

(2008) T. M. E. Davis et al.   DIABETOLOGIA